The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Gilead Sciences Inc

Nasdaq: GILD
Last

(U.S.) $100.32

Today's change+0.02 +0.02%
Updated November 28 1:00 PM EST. Delayed by at least 15 minutes.
 

Gilead Sciences Inc

Nasdaq: GILD
Last

(U.S.) $100.32

Today's change+0.02 +0.02%
Updated November 28 1:00 PM EST. Delayed by at least 15 minutes.

Gilead Sciences Inc up slightly

Gilead Sciences Inc closed up just (U.S.)$0.02 Friday to (U.S.)$100.32. Shares have lost 0.26% over the last five days, but have gained 33.58% over the last year to date. This security has outperformed the S&P 500 by 20.02% during the last year.

Key company metrics

  • Open(U.S.) $100.99
  • Previous close(U.S.) $100.30
  • High(U.S.) $101.33
  • Low(U.S.) $99.70
  • Bid / Ask(U.S.) $100.14 / (U.S.) $100.37
  • YTD % change+33.58%
  • Volume7,501,108
  • Average volume (10-day)17,151,920
  • Average volume (1-month)16,758,498
  • Average volume (3-month)15,654,020
  • 52-week range(U.S.) $63.50 to (U.S.) $116.83
  • Beta0.70
  • Trailing P/E17.74×
  • P/E 1 year forward12.61×
  • Forward PEG0.49×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $5.65
Updated November 28 1:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+45.34%

Based on its net profit margin of 45.34%, Gilead Sciences Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.90%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue6,0426,5354,9993,120
Total other revenue--------
Total revenue6,0426,5354,9993,120
Gross profit5,0555,6104,1862,262
Total cost of revenue987925813858
Total operating expense2,5632,1221,9561,923
Selling / general / administrative945614548513
Research & development630584595552
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income3,4794,4133,0431,197
Interest income (expense), net non-operating-103-102-76-73
Gain (loss) on sale of assets--------
Other--------
Income before tax3,3714,3072,9481,113
Income after tax2,7243,6502,223787
Income tax, total647657726326
Net income2,7313,6562,227791
Total adjustments to net income--------
Net income before extra. items2,7313,6562,227791
Minority interest7555
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items2,7313,6562,227791
Inc. avail. to common incl. extra. items2,7313,6562,227791
Diluted net income2,7313,6562,227791
Dilution adjustment--------
Diluted weighted average shares1,6371,6641,6801,710
Diluted EPS excluding extraordinary itemsvalue per share1.672.201.330.46
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.672.201.330.46